Skip to content
value.today

TransCode Therapeutics, Inc.

RNAZ
$3 Mmarket cap on Aug 1, 2026-25.0% since Jan 2024
Compare
World rank
#27,383
Revenue
—
For year ending December-2025
Net income
$-35 M
SEC filing
Employees
12
As of April 3, 2026
SEC filing

TransCode Therapeutics, Inc. in brief

TransCode Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Boston, Massachusetts, USA. Its market value was $3 M on 1 August 2026, which makes it the 27,383rd largest listed company in the world and the 4,464th largest in the USA on this site. It employs about 12 people. Its shares trade under the symbol RNAZ (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About TransCode Therapeutics, Inc.

TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers. Our lead therapeutic product candidate is TTX-MC138, an antisense inhibitor of an oncogenic microRNA. TTX-MC138 has recently completed a Phase 1a clinical trial. In addition to other RNA-targeted product candidates, we are conducting research and development of a cancer vaccine product candidate and an oncolytic immunotherapy platform.

Polynoma Acquisition. On October 8, 2025, we entered into a Membership Interest Purchase Agreement with DEFJ, LLC, a Delaware limited liability company, pursuant to which we acquired 100% of the issued and outstanding membership interests of ABCJ, LLC, a Delaware limited liability company,. In the Acquisition, we issued 1,152.9568 shares of our Series A Non-Voting Convertible Preferred Stock to DEFJ. Each share of Series A Preferred Stock is convertible into 10,000 shares of common stock. Prior to the Acquisition, ABCJ was a wholly owned subsidiary of DEFJ and an indirect wholly owned subsidiary of CK Life Sciences Int’l., (Holdings) Inc., a listed entity on the Main Board of the Hong Kong Stock Exchange.

From the company's annual report filed with the US SEC: read the report

TransCode Therapeutics, Inc. timeline

2 events, 2020–2021
  1. 2020
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2021
  4. 🔔
    · approximate
    Initial public offering on Nasdaq

Events of TransCode Therapeutics, Inc. from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$8 M$17 M$25 M$33 M2023202420252026

World rank over time

▲ up 5,150 places since 2022
2022-01-07: #29048#29,04820222022-12-25: #32796#32,79620222023-07-30: #33351#33,35120232024-01-05: #32619#32,61920242026-03-08: #12816#12,81620262026-08-01: #23898#23,8982026

Rank in USA: #5,158 (Jan 2022) · #5,759 (Dec 2022) · #5,654 (Jul 2023) · #4,656 (Jan 2024) · #2,390 (Mar 2026) · #4,158 (Aug 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.3×
Free cash flow yield
-651.0%
Net margin
—
Operating margin
—
Return on equity
-335.2%
Liabilities / assets
6.5%
Profit per employee
$-2.9 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-2M—FY20Fiscal year ending Dec 2021: revenue —, net income $-7M—FY21Fiscal year ending Dec 2022: revenue —, net income $-18M—FY22Fiscal year ending Dec 2023: revenue —, net income $-19M—FY23Fiscal year ending Dec 2024: revenue —, net income $-17M—FY24Fiscal year ending Dec 2025: revenue —, net income $-35M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-28M$-35M—
Dec 2024——$-16M$-17M—
Dec 2023——$-19M$-19M—
Dec 2022——$-19M$-18M—
Dec 2021——$-6M$-7M—
Dec 2020——$-1M$-2M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-20M$0M$-20M$-52.59—
Dec 2024$-13M$0M$-13M$-1336.63—
Dec 2023$-18M$0M$-18M$-3419.01—
Dec 2022$-16M$0M$-16M$-1082.79—
Dec 2021$-5M$0M$-6M$-0.81—
Dec 2020$-0M——$-0.51—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue —, net income $-2M—Sep ’24Three months to Dec 2024 (from the annual report): revenue —, net income $-6M—Dec ’24Three months to Mar 2025: revenue —, net income $-12M—Mar ’25Three months to Jun 2025: revenue —, net income $-4M—Jun ’25Three months to Sep 2025: revenue —, net income $-5M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-13M—Dec ’25Three months to Mar 2026: revenue —, net income $-18M—Mar ’26Three months to Jun 2026: revenue —, net income $-7M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of TransCode Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-28 M
Net income
$-35 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$162 M
Total liabilities
$11 M
Total equity
$10 M

As of December-2025

Top 13 institutional investors in TransCode Therapeutics, Inc.#

As of Sep 30, 2026
13 institutions held 100,375 shares (about 0.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 0.6%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 13 largest institutional investors in TransCode Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Yorkville Advisors Global, LP75,786+56,147 (+285.90%)0.45%$0 MNov 12, 2026
2Citadel Advisors LLC10,207New0.06%$0 MNov 16, 2026
3Vanguard Capital Management LLC6,5450 (0.00%)0.04%$0 MNov 13, 2026
4Vanguard Fiduciary Trust Co2,9820 (0.00%)0.02%$0 MNov 13, 2026
5UBS Group AG2,650-238 (-8.24%)0.02%$0 MNov 10, 2026
6Tower Research Capital LLC (TRC)1,746+1,069 (+157.90%)0.01%$0 MNov 16, 2026
7Osaic Holdings, Inc.270New0.00%$0 MNov 12, 2026
8Robinhood Markets, Inc.102—0.00%$0 MNov 18, 2026
9Wells Fargo & Company/mn550 (0.00%)0.00%$0 MNov 16, 2026
10SBI Securities Co., Ltd.120 (0.00%)0.00%$0 MOct 22, 2026
11FMR LLC11-695 (-98.44%)0.00%$0 MNov 10, 2026
12IFP Advisors, Inc8New0.00%$0 MOct 16, 2026
13Northwestern Mutual Wealth Management Co1New0.00%$0 MNov 13, 2026

Mutual funds holding TransCode Therapeutics, Inc.#

4 funds hold shares worth $0 M (about 0.1% of the company). Since their previous reports 1 added shares and 0 sold, buying $0 M net.
Mutual funds holding TransCode Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC8,492$0 M0.05%<0.01%+47%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.6,545$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC1,180$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC510$0 M<0.01%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at TransCode Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
3
since
TransCode Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed CK Life Sciences Intl (Holdings) Inc10% ownerConversion+11.81 M——12.11 MForm 4
filed CK Life Sciences Intl (Holdings) Inc10% ownerConversion+2.02 M——14.13 MForm 4
filed Thomas A. FitzgeraldChief Financial Officer, DirectorBuy+49,350$0.510$25 K56,318Form 4
filed Robert Michael DudleyChief Executive Officer, DirectorBuy+98,000$0.510$50 K180,262Form 4
filed Robert Michael DudleyChief Executive Officer, DirectorBuy+12,000$2.650$32 K82,262Form 4
filed Robert Michael DudleyChief Executive Officer, DirectorBuy+6,607$2.550$17 K70,262Form 4
filed Robert Michael DudleyChief Executive Officer, DirectorBuyamended+19,000$2.760$52 K61,155Form 4/A
filed Robert Michael DudleyChief Executive Officer, DirectorBuy+19,000$2.760$52 K912,114Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: TransCode Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
52,014
5.7% of shares · 1.96 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-28.01 reverse split ; 1-for-33.33 reverse split ; 1-for-1 split in the period to ; 1-for-40 reverse split ; 1-for-20 reverse split ; 1.649-for-1 split

Trading halts

  • 2025-10-08 13:49 UTC, code LUDP, resumed 13:54 UTC
  • 2025-10-08 13:39 UTC, code LUDP, resumed 13:44 UTC
  • 2025-07-23 15:27 UTC, code LUDP, resumed 15:32 UTC
  • 2025-05-14 23:50 UTC, code T3, resumed 13:00 UTC
  • 2025-02-26 15:18 UTC, code LUDP, resumed 15:23 UTC

Fails to deliver

  • : 17,026 shares at $1.73
  • : 1,155 shares at $1.77
  • : 857 shares at $1.77
  • : 1,927 shares at $1.73
  • : 3,289 shares at $1.68

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

TransCode Therapeutics, Inc. scorecard#

Passes 1 of the 7 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-52.59 vs -1336.63Diluted EPS -52.59 in fiscal 2025 against -1336.63 the year before (report's currency).
    • ✗Net income higher than five years earlier-$35 M-$35 M in fiscal 2025 against -$2 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$35 MNet income -$35 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-833.2%-833.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities6.3×Current ratio 6.30 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

TransCode Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

TransCode Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Research and development139.712102.80.3
General and administrative5.86.07.28.4r3.40.4
Operating expenses28161919r6.20.7
Operating income−28−16−19−19r−6.2−0.7
Interest and finance income0.10.00.00.00.00.0
Interest expense and finance costs0.00.00.10.00.10.4
Other non-operating income (expense)−6.5−1.10.91.1r−0.7−1.6
Income before tax−34−17————
Income tax0.20000.10
Net income including minority interests−35−17−19−18−6.8−2.3
Net income attributable to shareholders−35−17−19−18−6.8−2.3
Earnings per share, basic-52.59-1,336.63r-3,419.01r-1,082.79r-0.81-0.51
Earnings per share, diluted-52.59-1,336.63r-3,419.01r-1,082.79r-0.81-0.51
Shares, weighted average (basic)0.70.0r0.0r0.0r8.44.6
Shares, weighted average (diluted)0.70.0r0.0r0.0r8.44.6
Balance sheet
Cash and cash equivalents185.82.85.0210.8
Other current assets0.91.31.72.11.90.0
Current assets227.14.57.4230.8
Property, plant and equipment0.40.10.10.20.2—
Right-of-use (leased) assets—0.00.5———
Goodwill26—————
Other intangible assets114—————
Total assets1627.35.27.6231.1
Accounts payable3.52.73.14.32.50.4
Current liabilities3.52.83.54.32.50.4
Lease liabilities (non-current)——0.0———
Non-current liabilities7.06.50.0——4.1
Total liabilities119.33.54.32.54.5
Retained earnings−98−63−46−28−10−3.5
Shareholders' equity10−2.01.63.220−3.4
Total liabilities and equity1627.35.27.6231.1
Shares outstanding0.90.0r0.0r0.0r134.6
Cash-flow statement
Depreciation and amortization0.10.10.10.10.00
Share-based compensation0.51.71.00.40.20.0
Cash from operating activities−20−13−18−16−5.3−0.5
Capital expenditure−0.0−0.0−0.0−0.1−0.3—
Cash from investing activities−0.0−0.0−0.0−0.1−0.3—
Shares issued8.916161.3——
Cash from financing activities3216160.0261.1
Change in cash123.0−2.2−16200.6
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at TransCode Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Debt called earlyFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Debt called early 1 · Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 6 · New debt 1 · Unregistered share sale 3 · Shareholder rights changed 5 · Bylaws or fiscal year changed 5 · Shareholder vote 2

TransCode Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Debt called earlyMaterial agreement8-K
Directors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Delisting notice8-K/A
Delisting notice8-K
Material agreementNew debtUnregistered share sale8-K
Unregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Directors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Material agreement8-K/A
Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Material agreement8-K/A
Material agreement8-K
Shareholder vote8-K
Delisting notice8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 1, 2026

Acquisitions and funding#

1 acquisitions, $140 M paid where reported

Businesses it acquired

Acquisitions by TransCode Therapeutics, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
ABCJ, LLC2025—$140 M100%Annual report

Private share sales · funding history

Private share sales of TransCode Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2024$8 MPrivate placement after listing$2 to $10 million6equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How TransCode Therapeutics, Inc. compares in Biotechnology

  • Market cap$3 M · higher than 2% of 726
  • Price / book0.3× · lower than 97% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
TransCode Therapeutics, Inc.🇺🇸$3 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of April 3, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at TransCode Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show TransCode Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about TransCode Therapeutics, Inc.? Suggest a correction